Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 130

1.

GSK2801, A BAZ2/BRD9 Bromodomain Inhibitor, Synergizes with BET Inhibitors to Induce Apoptosis in Triple-Negative Breast Cancer.

Bevill SM, Olivares-Quintero JF, Sciaky N, Golitz BT, Singh D, Beltran AS, Rashid NU, Stuhlmiller TJ, Hale A, Moorman NJ, Santos CM, Angus SP, Zawistowski JS, Johnson GL.

Mol Cancer Res. 2019 Apr 18. doi: 10.1158/1541-7786.MCR-18-1121. [Epub ahead of print]

PMID:
31000582
2.

Design of a Cyclin G Associated Kinase (GAK)/Epidermal Growth Factor Receptor (EGFR) Inhibitor Set to Interrogate the Relationship of EGFR and GAK in Chordoma.

Asquith CRM, Naegeli KM, East MP, Laitinen T, Havener TM, Wells CI, Johnson GL, Drewry DH, Zuercher WJ, Morris DC.

J Med Chem. 2019 May 9;62(9):4772-4778. doi: 10.1021/acs.jmedchem.9b00350. Epub 2019 Apr 19.

PMID:
30973735
3.

Far away from the lamppost.

Oprea TI, Jan L, Johnson GL, Roth BL, Ma'ayan A, Schürer S, Shoichet BK, Sklar LA, McManus MT.

PLoS Biol. 2018 Dec 11;16(12):e3000067. doi: 10.1371/journal.pbio.3000067. eCollection 2018 Dec.

4.

Best practices for implementing venous thromboembolism prophylaxis across the continuum of care.

Dobesh PP, Ahuja T, Davis GA, Fatodu H, Francis WH, Hull FP, Johnson GL, Lenchus JD, Lenoir JG, McPherson C, Nemeth J, Riello RJ 3rd.

Am J Manag Care. 2018 Nov;24(22 Suppl):S483-S488. No abstract available.

5.

The use of betrixaban for extended prophylaxis of venous thromboembolism events in hospitalized, high-risk patients.

Dobesh PP, Ahuja T, Davis GA, Fatodu H, Francis WH, Hull FP, Johnson GL, Lenchus JD, Lenoir JG, McPherson C, Nemeth J, Riello RJ 3rd.

Am J Manag Care. 2018 Nov;24(22 Suppl):S475-S482. No abstract available.

6.

Venous thromboembolism in acute medically ill patients: identifying unmet needs and weighing the value of prophylaxis.

Dobesh PP, Ahuja T, Davis GA, Fatodu H, Francis WH, Hull FP, Johnson GL, Lenchus JD, Lenoir JG, McPherson C, Nemeth J, Riello RJ 3rd.

Am J Manag Care. 2018 Nov;24(22 Suppl):S468-S474. No abstract available.

7.

A proteasome-resistant fragment of NIK mediates oncogenic NF-κB signaling in schwannomas.

Gehlhausen JR, Hawley E, Wahle BM, He Y, Edwards D, Rhodes SD, Lajiness JD, Staser K, Chen S, Yang X, Yuan J, Li X, Jiang L, Smith A, Bessler W, Sandusky G, Stemmer-Rachamimov A, Stuhlmiller TJ, Angus SP, Johnson GL, Nalepa G, Yates CW, Wade Clapp D, Park SJ.

Hum Mol Genet. 2019 Feb 15;28(4):572-583. doi: 10.1093/hmg/ddy361.

PMID:
30335132
8.

EPH receptor signaling as a novel therapeutic target in NF2-deficient meningioma.

Angus SP, Oblinger JL, Stuhlmiller TJ, DeSouza PA, Beauchamp RL, Witt L, Chen X, Jordan JT, Gilbert TSK, Stemmer-Rachamimov A, Gusella JF, Plotkin SR, Haggarty SJ, Chang LS, Johnson GL, Ramesh V; Children’s Tumor Foundation Synodos for NF2 Consortium .

Neuro Oncol. 2018 Aug 2;20(9):1185-1196. doi: 10.1093/neuonc/noy046.

PMID:
29982664
9.

Traditional and systems biology based drug discovery for the rare tumor syndrome neurofibromatosis type 2.

Synodos for NF2 Consortium, Allaway R, Angus SP, Beauchamp RL, Blakeley JO, Bott M, Burns SS, Carlstedt A, Chang LS, Chen X, Clapp DW, Desouza PA, Erdin S, Fernandez-Valle C, Guinney J, Gusella JF, Haggarty SJ, Johnson GL, La Rosa S, Morrison H, Petrilli AM, Plotkin SR, Pratap A, Ramesh V, Sciaky N, Stemmer-Rachamimov A, Stuhlmiller TJ, Talkowski ME, Welling DB, Yates CW, Zawistowski JS, Zhao WN.

PLoS One. 2018 Jun 13;13(6):e0197350. doi: 10.1371/journal.pone.0197350. eCollection 2018.

10.

Application of Integrated Drug Screening/Kinome Analysis to Identify Inhibitors of Gemcitabine-Resistant Pancreatic Cancer Cell Growth.

Krulikas LJ, McDonald IM, Lee B, Okumu DO, East MP, Gilbert TSK, Herring LE, Golitz BT, Wells CI, Axtman AD, Zuercher WJ, Willson TM, Kireev D, Yeh JJ, Johnson GL, Baines AT, Graves LM.

SLAS Discov. 2018 Sep;23(8):850-861. doi: 10.1177/2472555218773045. Epub 2018 May 9.

PMID:
29742358
11.

Proteomic analysis defines kinase taxonomies specific for subtypes of breast cancer.

Collins KAL, Stuhlmiller TJ, Zawistowski JS, East MP, Pham TT, Hall CR, Goulet DR, Bevill SM, Angus SP, Velarde SH, Sciaky N, Oprea TI, Graves LM, Johnson GL, Gomez SM.

Oncotarget. 2018 Jan 29;9(21):15480-15497. doi: 10.18632/oncotarget.24337. eCollection 2018 Mar 20.

12.

Unexplored therapeutic opportunities in the human genome.

Oprea TI, Bologa CG, Brunak S, Campbell A, Gan GN, Gaulton A, Gomez SM, Guha R, Hersey A, Holmes J, Jadhav A, Jensen LJ, Johnson GL, Karlson A, Leach AR, Ma'ayan A, Malovannaya A, Mani S, Mathias SL, McManus MT, Meehan TF, von Mering C, Muthas D, Nguyen DT, Overington JP, Papadatos G, Qin J, Reich C, Roth BL, Schürer SC, Simeonov A, Sklar LA, Southall N, Tomita S, Tudose I, Ursu O, Vidovic D, Waller A, Westergaard D, Yang JJ, Zahoránszky-Köhalmi G.

Nat Rev Drug Discov. 2018 May;17(5):377. doi: 10.1038/nrd.2018.52. Epub 2018 Mar 23.

PMID:
29567993
13.

Unexplored therapeutic opportunities in the human genome.

Oprea TI, Bologa CG, Brunak S, Campbell A, Gan GN, Gaulton A, Gomez SM, Guha R, Hersey A, Holmes J, Jadhav A, Jensen LJ, Johnson GL, Karlson A, Leach AR, Ma'ayan A, Malovannaya A, Mani S, Mathias SL, McManus MT, Meehan TF, von Mering C, Muthas D, Nguyen DT, Overington JP, Papadatos G, Qin J, Reich C, Roth BL, Schürer SC, Simeonov A, Sklar LA, Southall N, Tomita S, Tudose I, Ursu O, Vidovic D, Waller A, Westergaard D, Yang JJ, Zahoránszky-Köhalmi G.

Nat Rev Drug Discov. 2018 May;17(5):317-332. doi: 10.1038/nrd.2018.14. Epub 2018 Mar 23. Review. Erratum in: Nat Rev Drug Discov. 2018 Mar 23;:.

14.

Mass Spectrometry-Based Proteomics Reveals Potential Roles of NEK9 and MAP2K4 in Resistance to PI3K Inhibition in Triple-Negative Breast Cancers.

Mundt F, Rajput S, Li S, Ruggles KV, Mooradian AD, Mertins P, Gillette MA, Krug K, Guo Z, Hoog J, Erdmann-Gilmore P, Primeau T, Huang S, Edwards DP, Wang X, Wang X, Kawaler E, Mani DR, Clauser KR, Gao F, Luo J, Davies SR, Johnson GL, Huang KL, Yoon CJ, Ding L, Fenyö D, Ellis MJ, Townsend RR, Held JM, Carr SA, Ma CX.

Cancer Res. 2018 May 15;78(10):2732-2746. doi: 10.1158/0008-5472.CAN-17-1990. Epub 2018 Feb 22.

15.

Discovery and characterization of an iminocoumarin scaffold as an inhibitor of MEKK2 (MAP3K2).

Ahmad S, St Hilaire VR, Dandepally SR, Johnson GL, Williams AL, Scott JE.

Biochem Biophys Res Commun. 2018 Jan 29;496(1):205-211. doi: 10.1016/j.bbrc.2018.01.027. Epub 2018 Jan 5.

16.

Enhancer remodeling regulates epigenetic adaptation and resistance to MEK1/2 inhibition in triple-negative breast cancer.

Bevill SM, Zawistowski JS, Johnson GL.

Mol Cell Oncol. 2017 Mar 31;4(6):e1300622. doi: 10.1080/23723556.2017.1300622. eCollection 2017.

17.

New Mechanisms of Resistance to MEK Inhibitors in Melanoma Revealed by Intravital Imaging.

Brighton HE, Angus SP, Bo T, Roques J, Tagliatela AC, Darr DB, Karagoz K, Sciaky N, Gatza ML, Sharpless NE, Johnson GL, Bear JE.

Cancer Res. 2018 Jan 15;78(2):542-557. doi: 10.1158/0008-5472.CAN-17-1653. Epub 2017 Nov 27.

18.

Competitive Kinase Enrichment Proteomics Reveals that Abemaciclib Inhibits GSK3β and Activates WNT Signaling.

Cousins EM, Goldfarb D, Yan F, Roques J, Darr D, Johnson GL, Major MB.

Mol Cancer Res. 2018 Feb;16(2):333-344. doi: 10.1158/1541-7786.MCR-17-0468. Epub 2017 Nov 13.

19.

Identification and Optimization of 4-Anilinoquinolines as Inhibitors of Cyclin G Associated Kinase.

Asquith CRM, Laitinen T, Bennett JM, Godoi PH, East MP, Tizzard GJ, Graves LM, Johnson GL, Dornsife RE, Wells CI, Elkins JM, Willson TM, Zuercher WJ.

ChemMedChem. 2018 Jan 8;13(1):48-66. doi: 10.1002/cmdc.201700663. Epub 2017 Nov 27.

20.

Kinome and Transcriptome Profiling Reveal Broad and Distinct Activities of Erlotinib, Sunitinib, and Sorafenib in the Mouse Heart and Suggest Cardiotoxicity From Combined Signal Transducer and Activator of Transcription and Epidermal Growth Factor Receptor Inhibition.

Stuhlmiller TJ, Zawistowski JS, Chen X, Sciaky N, Angus SP, Hicks ST, Parry TL, Huang W, Beak JY, Willis MS, Johnson GL, Jensen BC.

J Am Heart Assoc. 2017 Oct 19;6(10). pii: e006635. doi: 10.1161/JAHA.117.006635.

Supplemental Content

Loading ...
Support Center